Gsk (GLAXF) Change in Accured Expenses (2009 - 2016)

Gsk's Change in Accured Expenses history runs 8 years deep, the most recent figure standing at -$1.0 billion for Q4 2016.

• In Q4 2016, Change in Accured Expenses fell 219.84% year-over-year to -$1.0 billion; the TTM figure through Dec 2016 stood at $607.6 million (down 63.66% YoY), while the FY2018 annual figure was $3.2 billion, up 40.65% from the prior year.
• Change in Accured Expenses was -$1.0 billion for Q4 2016 at Gsk, down from $246.5 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $1.1 billion in Q3 2014 to a low of -$1.0 billion in Q4 2016.
• Historically, Change in Accured Expenses has averaged -$149.1 million across 5 years, with a median of -$430.8 million in 2013.
• The sharpest annual moves came in 2015 and 2016: Change in Accured Expenses soared 210.02% in 2015, then tumbled 219.84% in 2016.
• A 5-year view of Change in Accured Expenses shows it stood at -$864.0 million in 2012, then soared by 62.52% to -$323.8 million in 2013, then tumbled by 140.24% to -$777.9 million in 2014, then jumped by 210.02% to $855.9 million in 2015, then tumbled by 219.84% to -$1.0 billion in 2016.
• The last three Change in Accured Expenses figures came in at -$1.0 billion (Q4 2016), $246.5 million (Q1 2016), and $855.9 million (Q4 2015), per Business Quant data.